Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz provided updates on the company's lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd(TM). The discussion underscored Quantum's dual strategy of advancing a novel therapy for multiple sclerosis while generating revenue from an over-the-counter product.
Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments. The company is preparing for a Phase 2 clinical trial, which will be the first study to evaluate Lucid-MS in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. According to the press release, Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
On the commercial front, unbuzzd(TM) is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. Quantum retains a 19.84% ownership stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the product at unbuzzd.com. The agreement also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The company's focus on both a high-potential therapeutic and a consumer product reflects a balanced approach to growth. For leaders in business and technology, this dual strategy may offer insights into how biopharmaceutical companies can leverage commercial products to fund research and development. The upcoming Phase 2 trial for Lucid-MS represents a critical milestone, as positive results could address a significant unmet need in multiple sclerosis treatment, potentially impacting millions of patients worldwide.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The full press release is available at https://ibn.fm/HURxt, and the latest news and updates relating to QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.
